Neuberger Berman Group »

Black Diamond Therapeutics shares owned by Neuberger Berman Group

Quarter-by-quarter ownership of Black Diamond Therapeutics (BDTX) shares owned by Neuberger Berman Group from 13F filings

Historical chart of Neuberger Berman Group investment in Black Diamond Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Black Diamond Therapeutics held by Neuberger Berman Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Black Diamond Therapeutics by Neuberger Berman Group

Quarter filed Position value Share count Share price at filing
2026-06-30 $19k 11k 1.85

More positions owned by Neuberger Berman Group

Nvidia Corp Common (NVDA)
Apple Common (AAPL)
Amazon Common (AMZN)
Microsoft Corp Common (MSFT)
Alphabet Inc Class A A Common (GOOGL)
Alphabet Inc-cl C Common (GOOG)
Jpmorgan Chase & Co Common (JPM)
Eli Lilly & Co Common (LLY)
Ishares Core S&p 500 Etf Etf (IVV)
Broadcom Common (AVGO)
Asml Holding Adr Representing Nv Common (ASML)
Meta Platforms Inc Class A A Common (META)
Home Depot Common (HD)
Nextera Energy Common (NEE)
Analog Devices Common (ADI)

View all positions for Neuberger Berman Group

Top funds holding Black Diamond Therapeutics

NEA Management Company
BlackRock
Acadian Asset Management
Vanguard Capital Management
Renaissance Technologies
Defilade Capital Management
Dimensional Fund Advisors
Geode Capital Management
Connor, Clark & Lunn Investment Management
AWM Investment Company
Marshall Wace
Bridgeway Capital Management
FMR
Balyasny Asset Management
Bank of America Corporation

View all funds holding Black Diamond Therapeutics